Key result
Factor XIa inhibitors emerge as promising DOAC substitutes to lower bleeding risk in elderly AF.
Why the study?
Although anticoagulation reduces stroke risk in non-valvular atrial fibrillation, bleeding remains a major concern, prompting the review of new molecules to minimize bleeding risk in elderly patients.
Do Factor XIa inhibitors provide effective stroke prevention with minimized bleeding risk compared to DOACs in patients aged 65 and older with non-valvular atrial fibrillation?
Design
Systematic review
Authors
Loading...
May support Factor XIa inhibitors in high-bleeding-risk elderly AF; leaves open confirmation of net benefit versus DOACs in RCTs.
Systematic Review
Do Factor XIa inhibitors provide effective stroke prevention with minimized bleeding risk compared to DOACs in patients aged 65 and older with non-valvular atrial fibrillation?
Factor XIa inhibitors represent a promising new class of oral anticoagulants that may offer a safer alternative to DOACs for stroke prevention in elderly patients with atrial fibrillation by potentially uncoupling thrombosis from hemostasis.
Santostasi et al. (2023) conducted a systematic review in Non-valvular atrial fibrillation. Factor XIa inhibitors vs. Direct oral anticoagulants (DOACs) was evaluated. Factor XIa inhibitors are emerging as promising candidates to substitute DOACs for stroke prevention in elderly patients with atrial fibrillation, potentially minimizing bleeding risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: